Repros Therapeutics files $20 million shelf covering stock, preferreds

By Devika Patel

Knoxville, Tenn., Dec. 10 - Repros Therapeutics Inc. filed a $20 million shelf in an S-3 filing with the Securities and Exchange Commission.

The registration covers common stock, preferred stock and warrants.

The preferreds may be structured as convertibles.

Proceeds will be used for general corporate purposes.

Repros Therapeutics, based in the Woodlands, Texas, develops drugs for the treatment of reproductive disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.